Literature DB >> 28344882

Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma.

Chuangzhong Deng1, Zaishang Li1, Shengjie Guo1, Peng Chen2, Xiaofeng Chen3, Qianghua Zhou1, Jieping Chen1, Xingsu Yu4, Xiaoliang Wu4, Wenjuan Ma4, Qiankun Xie4, Yunlin Ye1, Yonghong Li1, Zike Qin1, Zhuowei Liu1, Ranyi Liu5, Zhenfeng Zhang4, Kai Yao1, Hui Han1, Fangjian Zhou1.   

Abstract

Despite its rare incidence worldwide, penile squamous cell carcinoma (PeSCC) still presents with significant morbidity and mortality due to the limited treatment options for advanced patients, especially those in developing countries. The program death-1 (PD-1)/PD-1 ligand (PD-L1) axis has been demonstrated to play an important role in tumor immune escape, and immunotherapies targeting this pathway have shown great success in certain cancer types. Here, we analyzed the expression pattern of PD-L1 in tumor cells and tumor-infiltrating lymphocytes (TILs) in PeSCC with a multi-center cohort. We found that the majority of PeSCCs (53.4%) were PD-L1-positive and that high PD-L1 expression in tumor cells was associated with a poor prognosis. Notably, PD-L1 expression in tumor cells was significantly associated with the extent of TILs and CD8+ TILs. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) showed that PD-L1 was positively correlated with interferon-gamma (IFNγ) and CD8+ gene expression. Moreover, we defined the constitutive and inducible surface expression of PD-L1 in newly established primary PeSCC cell lines. Interestingly, two PeSCC cell lines had high intrinsic PD-L1 expression. Another cell line showed low PD-L1 expression, but the PD-L1 expression could be induced by IFNγ stimulation. Overall, our data showed that high PD-L1 expression in penile tumor cells indicated a poor prognosis. The upregulation of PD-L1 in PeSCC included both extrinsic and intrinsic mechanisms. These findings indicated that the PD-1/PD-L1 axis might be a potential therapeutic target for patients with penile squamous cell carcinoma.

Entities:  

Keywords:  IFNγ; PD-L1; immunohistochemistry; penile cancer; penile cancer cell line; tumor-infiltrating lymphocytes

Year:  2016        PMID: 28344882      PMCID: PMC5353932          DOI: 10.1080/2162402X.2016.1269047

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  38 in total

1.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

2.  IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells.

Authors:  Sang-Keun Lee; Sam-Hwa Seo; Byoung-Soo Kim; Chang-Deok Kim; Jeung-Hoon Lee; Jung-Soo Kang; Pil Jae Maeng; Jong-Soon Lim
Journal:  J Dermatol Sci       Date:  2005-08-08       Impact factor: 4.563

3.  EAU guidelines on penile cancer: 2014 update.

Authors:  Oliver W Hakenberg; Eva M Compérat; Suks Minhas; Andrea Necchi; Chris Protzel; Nick Watkin
Journal:  Eur Urol       Date:  2014-11-01       Impact factor: 20.096

4.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor.

Authors:  Anna M Dahlin; Maria L Henriksson; Bethany Van Guelpen; Roger Stenling; Ake Oberg; Jörgen Rutegård; Richard Palmqvist
Journal:  Mod Pathol       Date:  2011-01-14       Impact factor: 7.842

7.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

Authors:  Brant A Inman; Thomas J Sebo; Xavier Frigola; Haidong Dong; Eric J Bergstralh; Igor Frank; Yves Fradet; Louis Lacombe; Eugene D Kwon
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

10.  Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.

Authors:  Roberto Bellucci; Allison Martin; Davide Bommarito; Kathy Wang; Steen H Hansen; Gordon J Freeman; Jerome Ritz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

View more
  18 in total

1.  Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers.

Authors:  Karina Cereceda; Nicolas Bravo; Roddy Jorquera; Roxana González-Stegmaier; Franz Villarroel-Espíndola
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

2.  Tumor-associated immune cell infiltrate density in penile squamous cell carcinomas.

Authors:  Luca Hladek; Katrin Bankov; Jens von der Grün; Natalie Filmann; Melanie Demes; Stefan Vallo; Peter J Wild; Ria Winkelmann
Journal:  Virchows Arch       Date:  2022-01-13       Impact factor: 4.535

3.  Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.

Authors:  Wen-Juan Ma; Xing Wang; Wen-Ting Yan; Zhong-Guo Zhou; Zhi-Zhong Pan; Gong Chen; Rong-Xin Zhang
Journal:  World J Gastroenterol       Date:  2018-05-28       Impact factor: 5.742

4.  Elevated serum LAMC2 is associated with lymph node metastasis and predicts poor prognosis in penile squamous cell carcinoma.

Authors:  Qiang-Hua Zhou; Chuang-Zhong Deng; Jie-Ping Chen; Kang-Bo Huang; Ting-Yu Liu; Kai Yao; Zhuo-Wei Liu; Zi-Ke Qin; Yong-Hong Li; Sheng-Jie Guo; Yun-Lin Ye; Fang-Jian Zhou; Wenlin Huang; Ran-Yi Liu; Hui Han
Journal:  Cancer Manag Res       Date:  2018-08-28       Impact factor: 3.989

5.  The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.

Authors:  Sarah Rosanne Ottenhof; Rosa Sanne Djajadiningrat; Helene Hoegsbro Thygesen; Pamela Josephine Jakobs; Katarzyna Jóźwiak; Anne Marijne Heeren; Jeroen de Jong; Joyce Sanders; Simon Horenblas; Ekaterina Straschimirova Jordanova
Journal:  Front Immunol       Date:  2018-06-11       Impact factor: 7.561

6.  PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.

Authors:  Zi-Qi Zhou; Jing-Jing Zhao; Qiu-Zhong Pan; Chang-Long Chen; Yuan Liu; Yan Tang; Qian Zhu; De-Sheng Weng; Jian-Chuan Xia
Journal:  J Immunother Cancer       Date:  2019-08-27       Impact factor: 13.751

7.  Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.

Authors:  Xuhan Zhang; Lu Liu; Shiyong Zhou; Kuo Zhao; Zheng Song; Ge Hu; Tingting Zhang; Yang Li; Lihua Qiu; Lanfang Li; Zhengzi Qian; Bin Meng; Yi Pan; Xiubao Ren; Xianhuo Wang; Huilai Zhang; Kai Fu
Journal:  Hematol Oncol       Date:  2019-05-30       Impact factor: 5.271

8.  Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review.

Authors:  Xiangyu Su; Jing Zhang; Chenchun Fu; Mingzhe Xiao; Cailian Wang
Journal:  Onco Targets Ther       Date:  2020-04-21       Impact factor: 4.147

9.  Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas.

Authors:  Christoph Arolt; Moritz Meyer; Alexander Quaas; Jens Peter Klussmann; Vanessa Ruesseler; Lisa Nachtsheim; Nora Wuerdemann; Thomas Dreyer; Stefan Gattenlöhner; Claus Wittekindt; Reinhard Buettner
Journal:  Cancer Immunol Immunother       Date:  2020-03-30       Impact factor: 6.968

10.  Predictors of inguinal lymph node metastasis in penile cancer patients: a meta-analysis of retrospective studies.

Authors:  Jiao Hu; Yu Cui; Peihua Liu; Xu Zhou; Wenbiao Ren; Jinbo Chen; Xiongbing Zu
Journal:  Cancer Manag Res       Date:  2019-07-10       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.